- Therapeutic Solutions International (TSOI, Financial) plans a voluntary delisting from public markets to refocus its business strategy.
- The company aims to regroup by prioritizing its subsidiaries: Breathe Biologics, Campbell Neurosciences, and Res Nova Bio.
- CEO Timothy G. Dixon promises potential future financial returns to shareholders after restructuring efforts.
Therapeutic Solutions International, Inc. (TSOI) has announced its intention to voluntarily delist from public markets. According to CEO Timothy G. Dixon, the decision, approved by the Board of Directors and a majority of voting shareholders, reflects a strategic move to withdraw from the Exchange and OTC Markets. TSOI will file the necessary documentation with the SEC, including Form 25 and Form 15, to complete this process.
The company has faced significant challenges, with its market cap declining from $400 million to below $10 million, and its stock trading at $0.0001. Dixon cites problems like predatory trading and toxic financings as contributing factors to the decision to "go dark" and reset.
During this regrouping phase, TSOI plans to concentrate on its subsidiaries, particularly Breathe Biologics, Campbell Neurosciences, and Res Nova Bio, which are seen as central to the company's technological and scientific future. These entities are expected to create significant monetization opportunities, potentially leading to liquidity through sales or partnerships.
Dixon assures shareholders of the company's commitment to their investment, expressing intentions to return a portion of future profits through dividends or stock buy-backs. This move signifies a dedication to rewarding the patience and faith of existing shareholders.
Therapeutic Solutions International continues its focus on immune modulation for the treatment of specific diseases. More information about the company can be found on its corporate website.
